<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Krämer et al.|Blood|2021Cited by 170
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Christian Thiede, Katja Sockel et al.|Blood|2025Cited by 5